JO2985B1 - مثبطات كينازmapk/erk - Google Patents

مثبطات كينازmapk/erk

Info

Publication number
JO2985B1
JO2985B1 JOP/2007/0555A JOP20070555A JO2985B1 JO 2985 B1 JO2985 B1 JO 2985B1 JO P20070555 A JOP20070555 A JO P20070555A JO 2985 B1 JO2985 B1 JO 2985B1
Authority
JO
Jordan
Prior art keywords
mapk
kinase inhibitors
compounds
erk kinase
methods
Prior art date
Application number
JOP/2007/0555A
Other languages
English (en)
Inventor
Toufike Kanouni
Xianchong Gong
Stephen W Kaldor
Feng Zhou
Qing Dong
Michael B Wallace
Nicholas Scorah
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Application granted granted Critical
Publication of JO2985B1 publication Critical patent/JO2985B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

يتعلق الاختراع الحالي بمركبات ( compounds) من الصيغه التالية للاستخدام مع MEK التي تشمل: حيث تكون المتغيرات كما تحدد هنا، كما يوفر ايضا تركيبات دوائية ( pharmaceutical compositions) مجموعات ( kits) وادوات ( articles) للتصنيع تشمل هذه المركبات ( compounds) الطرق ( methods) والمركبات الوسطية ( intermediates) المفيدة لتصنيع المركبات ( compounds) وطرق ( methods) لاستخدام المركبات( compounds) المذكورة.
JOP/2007/0555A 2006-12-20 2007-12-17 مثبطات كينازmapk/erk JO2985B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87091306P 2006-12-20 2006-12-20

Publications (1)

Publication Number Publication Date
JO2985B1 true JO2985B1 (ar) 2016-09-05

Family

ID=39462025

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2007/0555A JO2985B1 (ar) 2006-12-20 2007-12-17 مثبطات كينازmapk/erk

Country Status (35)

Country Link
US (4) US8293901B2 (ar)
EP (1) EP2125810B1 (ar)
JP (1) JP5513127B2 (ar)
KR (1) KR101488467B1 (ar)
CN (1) CN101679411B (ar)
AR (1) AR064640A1 (ar)
AU (1) AU2007337003B2 (ar)
BR (1) BRPI0720525B8 (ar)
CA (1) CA2673647C (ar)
CL (1) CL2007003742A1 (ar)
CO (1) CO6230984A2 (ar)
CR (1) CR10937A (ar)
DK (1) DK2125810T3 (ar)
EA (1) EA016312B1 (ar)
EC (1) ECSP099529A (ar)
ES (1) ES2430966T3 (ar)
GE (1) GEP20125511B (ar)
HR (1) HRP20130684T1 (ar)
IL (1) IL199362A (ar)
JO (1) JO2985B1 (ar)
MA (1) MA31151B1 (ar)
MX (1) MX2009006675A (ar)
MY (1) MY157871A (ar)
NO (1) NO342270B1 (ar)
NZ (1) NZ578310A (ar)
PE (1) PE20090071A1 (ar)
PL (1) PL2125810T3 (ar)
PT (1) PT2125810E (ar)
RS (1) RS52887B (ar)
SI (1) SI2125810T1 (ar)
TN (1) TN2009000249A1 (ar)
TW (1) TWI396538B (ar)
UA (1) UA98479C2 (ar)
WO (1) WO2008079814A2 (ar)
ZA (1) ZA200904682B (ar)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1790649A1 (en) * 2005-11-21 2007-05-30 Sanofi-Aventis Substituted bicyclic pyrimidone derivatives
TW200800997A (en) * 2006-03-22 2008-01-01 Astrazeneca Ab Chemical compounds
BRPI0717374A2 (pt) * 2006-10-23 2013-10-29 Takeda Pharmaceutical Inibidores de mapk/erk quinase
JO2985B1 (ar) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
SA08280783B1 (ar) * 2007-01-11 2011-04-24 استرازينيكا ايه بي مشتقات بيريدوبيريميدين كمثبطات pde4
EP2150544B1 (en) * 2007-03-19 2016-01-13 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
WO2009064675A1 (en) * 2007-11-12 2009-05-22 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
WO2009146034A2 (en) * 2008-03-31 2009-12-03 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
CA2742785A1 (en) * 2008-11-18 2010-05-27 Takeda Pharmaceutical Company Limited Process for making (r) -3-(2,3-dihydroxypropyl)-6-fluoro-5-(2-flouro-4-iodophenylamino)-8-methylpyrido[2,3-d]pyrimidine-4,7(3h,8h)-dione and intermediates thereof
EP2588107A1 (en) 2010-07-01 2013-05-08 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
TWI505828B (zh) * 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
AR086656A1 (es) * 2011-06-03 2014-01-15 Millennium Pharm Inc Combinacion de inhibidores de mek e inhibidores selectivos de la quinasa aurora a
PH12015501654A1 (en) 2012-03-01 2017-04-10 Genentech Inc Serine/threonine kinase inhibitors
JP2015511632A (ja) * 2012-03-30 2015-04-20 武田薬品工業株式会社 メラノーマの治療におけるｒａｆ阻害剤およびｍｅｋ阻害剤の投与
EP3159342B1 (en) * 2014-06-17 2020-08-05 Cisen Pharmaceutical Co., Ltd. Pyridino[1,2-a]pyrimidone analogue used as mtor/pi3k inhibitor
WO2016009306A1 (en) * 2014-07-15 2016-01-21 Lupin Limited Heterocyclyl compounds as mek inhibitors
KR101671404B1 (ko) * 2014-09-02 2016-11-02 한국원자력의학원 항암 효과, 방사선 병용치료 효과 및 당뇨병 치료 효과를 갖는 피리미딘 유도체 및 이의 의학적 용도
JP2016155776A (ja) * 2015-02-24 2016-09-01 学校法人兵庫医科大学 抗腫瘍効果増強剤および抗腫瘍剤
RU2742234C1 (ru) * 2017-06-23 2021-02-03 Систоун Фармасьютикалс Кумариноподобное циклическое соединение в качестве ингибитора мек и его применение
GB201713975D0 (en) 2017-08-31 2017-10-18 Macrophage Pharma Ltd Medical use
CA3120337A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Naphthyridinone-aniline compounds for treatment of dermal disorders
TWI825637B (zh) 2021-03-31 2023-12-11 美商輝瑞股份有限公司 啶－１，６（２ｈ，７ｈ）－二酮

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5430148A (en) 1992-03-31 1995-07-04 Agouron Pharmaceuticals, Inc. Antiproliferative quinazolines
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
EE200100373A (et) 1999-01-13 2002-10-15 Warner-Lambert Company Bensoheterotsüklid ja nende kasutamine MEK inhibiitoritena
CN1395578A (zh) 2000-01-25 2003-02-05 沃尼尔·朗伯公司 吡啶并[2,3－d]嘧啶－2,7－二胺激酶抑制剂
SK288317B6 (sk) 2000-07-19 2015-11-03 Warner-Lambert Company Oxygénované estery 4-jódfenylaminobenzhydroxámových kyselín
ES2372028T3 (es) 2000-10-23 2012-01-13 Glaxosmithkline Llc Nuevo compuesto de 8h-pirido[2,3-d]pirimidin-7-ona trisustituida para el tratamiento de enfermedades mediadas por la csbp/p38 quinasa.
US6825180B2 (en) 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
AR038971A1 (es) 2002-03-13 2005-02-02 Array Biopharma Inc Derivados de bencimidazol n3 alquilado como inhibidores de mek
DOP2003000614A (es) 2002-03-13 2009-09-30 Array Biopharma Inc Derivados de bencimidazol n3 alquilado como inhibidores de mek (n3 alkylated benzimidazole
EP1636228B1 (de) * 2003-05-23 2008-10-22 AEterna Zentaris GmbH Neue pyridopyrazine und deren verwendung als modulatoren von kinasen
WO2005002351A2 (en) 2003-07-03 2005-01-13 Sunghag Koo Ferment ginseng oil
EP1651214B1 (en) * 2003-07-24 2009-09-16 Warner-Lambert Company LLC Benzimidazole derivatives as mek inhibitors
CN1860118A (zh) * 2003-07-29 2006-11-08 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
PT2251327E (pt) 2003-11-19 2014-03-04 Array Biopharma Inc Inibidores heterocíclicos de mek
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
ATE383360T1 (de) * 2004-06-11 2008-01-15 Japan Tobacco Inc 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h- pyrido(2,3-d)pyrimidinderivate und verwandte verbindungen zur behandlung von krebs
DE102004054215A1 (de) 2004-11-10 2006-05-11 Merck Patent Gmbh Pyridopyrimidinonderivate
ES2330872T3 (es) 2004-12-01 2009-12-16 Merck Serono Sa Derivados de (1,2,4)triazolo(4,3-a)piridina para el tratamiento de enfermedades hiperproliferativas.
WO2008010964A1 (en) 2006-07-17 2008-01-24 Merck & Co., Inc. 1-hydroxy naphthyridine compounds as anti-hiv agents
BRPI0717374A2 (pt) * 2006-10-23 2013-10-29 Takeda Pharmaceutical Inibidores de mapk/erk quinase
CN101535308A (zh) 2006-11-09 2009-09-16 霍夫曼-拉罗奇有限公司 作为激酶抑制剂的取代的6-苯基-吡啶并[2，3-d]嘧啶-7-酮衍生物及其使用方法
JO2985B1 (ar) * 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
WO2009064675A1 (en) * 2007-11-12 2009-05-22 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
WO2009146034A2 (en) * 2008-03-31 2009-12-03 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
CA2742785A1 (en) * 2008-11-18 2010-05-27 Takeda Pharmaceutical Company Limited Process for making (r) -3-(2,3-dihydroxypropyl)-6-fluoro-5-(2-flouro-4-iodophenylamino)-8-methylpyrido[2,3-d]pyrimidine-4,7(3h,8h)-dione and intermediates thereof

Also Published As

Publication number Publication date
ZA200904682B (en) 2010-09-29
CA2673647A1 (en) 2008-07-03
PL2125810T3 (pl) 2013-09-30
CN101679411B (zh) 2013-04-17
JP5513127B2 (ja) 2014-06-04
JP2010514680A (ja) 2010-05-06
US8470837B2 (en) 2013-06-25
CR10937A (es) 2009-11-20
WO2008079814A3 (en) 2008-09-04
US8293901B2 (en) 2012-10-23
US8030317B2 (en) 2011-10-04
SI2125810T1 (sl) 2013-09-30
PT2125810E (pt) 2013-07-29
NZ578310A (en) 2012-01-12
HRP20130684T1 (en) 2013-10-11
AU2007337003A2 (en) 2009-07-30
CO6230984A2 (es) 2010-12-20
PE20090071A1 (es) 2009-04-04
EA200970605A1 (ru) 2009-12-30
DK2125810T3 (da) 2013-07-29
EA016312B1 (ru) 2012-04-30
GEP20125511B (en) 2012-05-10
NO20092692L (no) 2009-09-16
AU2007337003A1 (en) 2008-07-03
CA2673647C (en) 2016-02-09
IL199362A (en) 2013-07-31
KR20090091353A (ko) 2009-08-27
WO2008079814A2 (en) 2008-07-03
UA98479C2 (en) 2012-05-25
EP2125810A2 (en) 2009-12-02
AR064640A1 (es) 2009-04-15
CN101679411A (zh) 2010-03-24
US20120202999A1 (en) 2012-08-09
US20080255160A1 (en) 2008-10-16
TN2009000249A1 (en) 2010-10-18
TW200835496A (en) 2008-09-01
AU2007337003B2 (en) 2013-05-02
EP2125810B1 (en) 2013-04-24
MY157871A (en) 2016-07-29
US20110065733A1 (en) 2011-03-17
US20100130518A1 (en) 2010-05-27
BRPI0720525A2 (pt) 2014-01-07
MX2009006675A (es) 2009-08-12
ES2430966T3 (es) 2013-11-22
NO342270B1 (no) 2018-04-30
TWI396538B (zh) 2013-05-21
BRPI0720525B8 (pt) 2021-05-25
ECSP099529A (es) 2009-08-28
KR101488467B1 (ko) 2015-01-30
RS52887B (en) 2014-02-28
BRPI0720525B1 (pt) 2020-03-03
CL2007003742A1 (es) 2008-06-13
MA31151B1 (ar) 2010-02-01

Similar Documents

Publication Publication Date Title
JO2985B1 (ar) مثبطات كينازmapk/erk
WO2009146034A3 (en) Mapk/erk kinase inhibitors and methods of use thereof
WO2008115890A3 (en) Mapk/erk kinase inhibitors
TN2010000131A1 (en) Polo-like kinase inhibitors
MY150542A (en) Cmet inhibitors
WO2007117995A3 (en) Kinase inhibitors
WO2008079787A3 (en) Glucokinase activators
WO2007104034A3 (en) Glucokinase activators
MY146989A (en) Kinase inhibitors
ATE479687T1 (de) Kinaseinhibitoren
WO2008116107A3 (en) Piperazine derivatives as glucokinase activators
WO2008053194A3 (en) Pyridine carboxamides as 11-beta-hsd1 inhibitors
WO2008055236A3 (en) Mapk/erk kinase inhibitors
WO2010111626A3 (en) Poly (adp-ribose) polymerase (parp) inhibitors
MX339476B (es) Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso.
WO2010008847A3 (en) Pi3k/m tor inhibitors
WO2009140624A3 (en) Glucokinase activators
PT2470546E (pt) Compostos de hexa-hidrooxazinopteridina para serem utilizados como inibidores de mtor
JO2822B1 (ar) مثبطات إنزيم كيناز p70 s6و akt
TN2009000151A1 (en) Mapk/erk kinase inhibitors
WO2008054956A3 (en) Kinase inhibitors
WO2008045834A3 (en) Kinase inhibitors
WO2009129401A8 (en) Kinase inhibitors
WO2008089005A3 (en) Renin inhibitors
TN2009000130A1 (en) Kinase inhibitors